Visiox Pharma, LLC
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Visiox Pharma, LLC - overview
Established
2019
Location
-, NY, US
Primary Industry
Biotechnology
About
Based in New York, US, and founded in 2021, Visiox Pharma, LLC, a. k. a. Visiox Pharma operates as a manufacturer of medicinal drugs called PDP-716 and SDN-037 that are used for treating eye diseases.
In August 2022, Visiox Pharma, LLC, raised USD 1. 30 million in seed funding led by Founding Partners. As of August 2023, Ryan Bleeks is the CEO of the company. The flagship product, Omlonti® (omidenepag isopropyl ophthalmic solution) 0.
002%, stands as an EP2 receptor agonist designed to combat ocular hypertension and open-angle glaucoma. PDP-716, an innovative once-daily brimonidine for ocular hypertension and open-angle glaucoma, follows the product suit. Additionally, SDN-037, a twice-daily topical difluprednate catering to post-surgical inflammation and pain. Visiox's strategic portfolio expansion includes TearActTM delivery technology, along with its acquisition of PDP-716 and SDN-037 from Sun Pharma Advanced Research Company Ltd.
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Optometrists & Opticians Products and Services
Website
www.visioxpharma.com
Verticals
Manufacturing
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.